Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID.
What Happened: The work is supported by foralumab's well-established role in de-activating microglia cells, a key component in this disease's pathogenesis.
Visteon (NASDAQ:VC) reported quarterly adj earnings of $1.58 per share which beat the analyst consensus estimate of $1.24 by 27.42 percent. This is a 777.78 percent increase over earnings of $0.18 per share from the same